Literature DB >> 18086530

Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production.

Huaqi Xiong1, Debbie Callaghan, Aimee Jones, Douglas G Walker, Lih-Fen Lue, Thomas G Beach, Lucia I Sue, John Woulfe, Huaxi Xu, Danica B Stanimirovic, Wandong Zhang.   

Abstract

Alzheimer's disease (AD) is characterized by overproduction of A beta derived from APP cleavage via beta- and gamma-secretase pathway. Recent evidence has linked altered cholesterol metabolism to AD pathogenesis. In this study, we show that AD brain had significant cholesterol retention and high beta- and gamma-secretase activities as compared to age-matched non-demented controls (ND). Over one-half of AD patients had an apoE4 allele but none of the ND. beta- and gamma-secretase activities were significantly stimulated in vitro by 40 and 80 microM cholesterol in AD and ND brains, respectively. Both secretase activities in AD brain were more sensitive to cholesterol (40 microM) than those of ND (80 microM). Filipin-stained cholesterol overlapped with BACE and A beta in AD brain sections. Cholesterol (10-80 microM) added to N2a cultures significantly increased cellular cholesterol, beta- and gamma-secretase activities and A beta secretion. Similarly, addition of cholesterol (20-80 microM) to cell lysates stimulated both in vitro secretase activities. Ergosterol slightly decreased beta-secretase activity at 20-80 microM, but strongly inhibited gamma-secretase activity at 40 microM. Cholesterol depletion reduced cellular cholesterol, beta-secretase activity and A beta secretion. Transcription factor profiling shows that several key nuclear receptors involving cholesterol metabolism were significantly altered in AD brain, including decreased LXR-beta, PPAR and TR, and increased RXR. Treatment of N2a cells with LXR, RXR or PPAR agonists strongly stimulated cellular cholesterol efflux to HDL and reduced cellular cholesterol and beta-/gamma-secretase activities. This study provides direct evidence that cholesterol homeostasis is impaired in AD brain and suggests that altered levels or activities of nuclear receptors may contribute to cholesterol retention which likely enhances beta- and gamma-secretase activities and A beta production in human brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086530      PMCID: PMC2720683          DOI: 10.1016/j.nbd.2007.10.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  61 in total

1.  Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease.

Authors:  Purnima Desai Sundar; Eleanor Feingold; Ryan L Minster; Steven T DeKosky; M Ilyas Kamboh
Journal:  Neurobiol Aging       Date:  2006-05-24       Impact factor: 4.673

2.  Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

Authors:  Taro E Akiyama; Shuichi Sakai; Gilles Lambert; Christopher J Nicol; Kimihiko Matsusue; Satish Pimprale; Ying-Hue Lee; Mercedes Ricote; Christopher K Glass; H Bryan Brewer; Frank J Gonzalez
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains.

Authors:  Suzanne Wahrle; Pritam Das; Andrew C Nyborg; Chris McLendon; Mikio Shoji; Takeshi Kawarabayashi; Linda H Younkin; Steven G Younkin; Todd E Golde
Journal:  Neurobiol Dis       Date:  2002-02       Impact factor: 5.996

4.  Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels.

Authors:  Hiroaki Fukumoto; Amy Deng; Michael C Irizarry; Michael L Fitzgerald; G William Rebeck
Journal:  J Biol Chem       Date:  2002-10-15       Impact factor: 5.157

5.  The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample.

Authors:  Bart Dermaut; Jessie Theuns; Kristel Sleegers; Hiroshi Hasegawa; Marleen Van den Broeck; Krist'l Vennekens; Ellen Corsmit; Peter St George-Hyslop; Marc Cruts; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Hum Genet       Date:  2002-04-24       Impact factor: 11.025

6.  Case-control study of presenilin-1 intronic polymorphism in sporadic early and late onset Alzheimer's disease.

Authors:  M Yasuda; N Hirono; K Maeda; T Imamura; E Mori; C Tanaka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

7.  Evaluation of multiple presenilin 2 SNPs for association with early-onset sporadic Alzheimer disease.

Authors:  W Mathias Howell; Anthony J Brookes
Journal:  Am J Med Genet       Date:  2002-08-01

Review 8.  A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation.

Authors:  Christoph Kaether; Christian Haass
Journal:  J Cell Biol       Date:  2004-12-06       Impact factor: 10.539

9.  Neuronal membrane cholesterol loss enhances amyloid peptide generation.

Authors:  Jose Abad-Rodriguez; Maria Dolores Ledesma; Katleen Craessaerts; Simona Perga; Miguel Medina; Andre Delacourte; Colin Dingwall; Bart De Strooper; Carlos G Dotti
Journal:  J Cell Biol       Date:  2004-12-06       Impact factor: 10.539

10.  LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells.

Authors:  Shubha Murthy; Ella Born; Satya N Mathur; F Jeffrey Field
Journal:  J Lipid Res       Date:  2002-07       Impact factor: 5.922

View more
  90 in total

1.  β-sitosterol inhibits high cholesterol-induced platelet β-amyloid release.

Authors:  Chun Shi; Jun Liu; Fengming Wu; Xiaoming Zhu; David T Yew; Jie Xu
Journal:  J Bioenerg Biomembr       Date:  2011-10-04       Impact factor: 2.945

Review 2.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 3.  Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease.

Authors:  Maria-Paz Marzolo; Guojun Bu
Journal:  Semin Cell Dev Biol       Date:  2008-10-17       Impact factor: 7.727

4.  Membrane cholesterol depletion reduces downstream signaling activity of the adenosine A2A receptor.

Authors:  Claire McGraw; Lewen Yang; Ilya Levental; Edward Lyman; Anne Skaja Robinson
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-01-08       Impact factor: 3.747

5.  Prostaglandin A1 Inhibits the Cognitive Decline of APP/PS1 Transgenic Mice via PPARγ/ABCA1-dependent Cholesterol Efflux Mechanisms.

Authors:  Guo-Biao Xu; Liu-Qing Yang; Pei-Pei Guan; Zhan-You Wang; Pu Wang
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 6.  Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.

Authors:  Rupinder K Sodhi; Nirmal Singh; Amteshwar S Jaggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-24       Impact factor: 3.000

Review 7.  Developmental and extrahepatic physiological functions of SREBP pathway genes in mice.

Authors:  Luke J Engelking; Mary Jo Cantoria; Yanchao Xu; Guosheng Liang
Journal:  Semin Cell Dev Biol       Date:  2017-07-20       Impact factor: 7.727

8.  Endoplasmic reticulum stress mediates amyloid β neurotoxicity via mitochondrial cholesterol trafficking.

Authors:  Elisabet Barbero-Camps; Anna Fernández; Anna Baulies; Laura Martinez; Jose C Fernández-Checa; Anna Colell
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

9.  Seladin-1 expression is regulated by promoter methylation in adrenal cancer.

Authors:  Lisa Simi; Francesca Malentacchi; Paola Luciani; Stefania Gelmini; Cristiana Deledda; Rosaria Arvia; Massimo Mannelli; Alessandro Peri; Claudio Orlando
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

10.  The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Authors:  Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz
Journal:  Alzheimers Res Ther       Date:  2010-07-14       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.